Is AEZS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,903 people get AEZS articles and Market Currents by email alert.

Get email alerts on AEZS »

HEADLINES:

Smaller Companies With Potential For Big Returns
Craig Keolanui • Thu, May 16 • 4 Comments
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

PR Newswire (Wed, 7:30AM)
Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

PR Newswire (May 8, 2013)
Æterna Zentaris Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results

PR Newswire (May 7, 2013)
Æterna Zentaris Inc. - Shareholder/Analyst Call
Thu, Apr 25
Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013

PR Newswire (Apr 23, 2013)
Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

PR Newswire (Apr 17, 2013)
David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.

PR Newswire (Apr 15, 2013)
Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting

PR Newswire (Apr 10, 2013)
Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer

PR Newswire (Apr 10, 2013)
Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting

PR Newswire (Apr 3, 2013)
Æterna Zentaris Management Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 22
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results

PR Newswire (Mar 21, 2013)
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
Stock Watch Wednesday, 20 March 2013
VFC's Stock House • Wed, Mar 20
Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference

PR Newswire (Mar 13, 2013)
Stock Watch Tuesday, 12 March 2013
VFC's Stock House • Tue, Mar 12 • 7 Comments
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013

PR Newswire (Mar 12, 2013)
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation

PR Newswire (Mar 11, 2013)

To learn more about Seeking Alpha Pro, click here.

Sentiment Shows Investors Bullish On Aeterna In 2013: Here's Why
LastFinancier • Fri, Jan 18 • 3 Comments
Can AEterna Turn A New Leaf In 2013?
Brian L. Wilson • Fri, Jan 4 • 2 Comments
AEterna Zentaris And Progenics Pharmaceuticals - Rising From The Ashes In 2013?
Chemistfrog • Tue, Dec 18, 2012 • 7 Comments
Aeterna Zentaris: Late-Stage Drug Candidates Could Send Stock Higher
Josh Hutheson • Mon, Nov 19, 2012 • 8 Comments
A Dismal 2012 May Make For A Good Entry Now For AEterna Zentaris
Chemistfrog • Tue, Nov 13, 2012
Aeterna Zentaris: Late-Stage Drug Development Company With An Enterprise Value Of Nearly Zero
Vineet Dutta • Wed, Oct 17, 2012 • 7 Comments
AEterna Zentaris' Pipeline Giving It A Lift As A Bottom Bounce Trade
MarketScanners • Thu, Oct 11, 2012 • 4 Comments
AEterna Zentaris: A Falling Knife Worth Catching?
Brian L. Wilson • Tue, Oct 9, 2012 • 3 Comments
Here We Go Again With AEterna Zentaris... Again
Stephen Simpson • Fri, Sep 21, 2012 • 23 Comments
Focus On Perifosine May Shift For AEterna Zentaris Investors
Brian L. Wilson • Wed, May 30, 2012 • 14 Comments
AEterna May Shoot Over $3/Share In The Near-Term
James Stocklasar Thomas Jr. • Wed, Mar 28, 2012 • 18 Comments
Is AEterna Zentaris Really Worth All This Fuss?
Stephen Simpson • Tue, Mar 13, 2012 • 47 Comments
The Other Side Of Keryx And AEterna
Adam Gefvert • Tue, Mar 6, 2012 • 80 Comments
FDA Approval Practically A Done Deal For Keryx And AEterna Zentaris
Jeremy Richards • Fri, Mar 2, 2012 • 78 Comments
AEterna Zentaris Is A Greatly Undervalued, Must-Buy Biotech
Jeremy Richards • Tue, Oct 11, 2011 • 15 Comments
AEterna Zentaris: The Very Best Biotech Under $2
James Stocklasar Thomas Jr. • Mon, Aug 22, 2011 • 8 Comments
AEterna Zentaris Looks Ready to Make New Highs
Jeremy Richards • Thu, Apr 21, 2011 • 6 Comments
AEterna Zentaris Offers Extreme Upside Reward
Jeremy Richards • Thu, Mar 31, 2011 • 11 Comments
Why AEterna Zentaris Still Retains 200% to 300% Upside Potential
Jeremy Richards • Wed, Feb 23, 2011 • 12 Comments
Analysts Say AEterna Zentaris Should Be Valued 200% to 300% Higher
Jeremy Richards • Fri, Dec 17, 2010 • 12 Comments

Smaller Companies With Potential For Big Returns
Craig Keolanui • Thu, May 16 • 4 Comments
Follow The Crashing Biotechs: 4 Stocks Fresh From A Fall
Craig Keolanui • Wed, Mar 20 • 4 Comments
Stock Watch Wednesday, 20 March 2013
VFC's Stock House • Wed, Mar 20
Stock Watch Tuesday, 12 March 2013
VFC's Stock House • Tue, Mar 12 • 7 Comments
Stock Watch Wednesday, 6 March 2013
VFC's Stock House • Wed, Mar 6 • 2 Comments
Stock Watch Thursday, 21 February 2013
VFC's Stock House • Thu, Feb 21 • 1 Comment
Cancer Stocks To Watch
BuySellShort • Mon, Feb 11 • 4 Comments
4 Small Cap Biopharmas With Near-Term Catalysts
Scott Matusow • Mon, Feb 11 • 22 Comments
Stock Watch Thursday, 7 February 2013
VFC's Stock House • Thu, Feb 7 • 4 Comments
Is Keryx Biopharmaceuticals A Good Buy At $9+?
InvestorR • Thu, Jan 31 • 72 Comments
Stock Watch Wednesday, 30 January 2013
VFC's Stock House • Wed, Jan 30 • 5 Comments
4 Small Biotechs With Big Clinical Trials Presenting In 2013
Brian L. Wilson • Wed, Jan 30 • 14 Comments
Stock Watch Tuesday, 29 January 2013
VFC's Stock House • Tue, Jan 29 • 4 Comments
Weekly Stock Watch, Week Of 28 January 2013
VFC's Stock House • Mon, Jan 28 • 1 Comment
2 Biotech Firms To Consider In The Wake Of Positive Clinical Data
Matt Schilling • Tue, Dec 11, 2012 • 1 Comment
Small Market Cap Pharmaceuticals With Large Catalysts Looming In 2013
Chemistfrog • Fri, Nov 30, 2012 • 5 Comments
Why Cash Overrules The Momentary Market Bounce
James Stocklasar Thomas Jr. • Tue, Nov 27, 2012 • 14 Comments
Why I'm 'In Cash' For Biotechs In A Bearish Market
James Stocklasar Thomas Jr. • Wed, Nov 21, 2012 • 37 Comments
4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce
MarketScanners • Tue, Nov 20, 2012 • 11 Comments
For Biotech Investors: 5 Orphan Drugs And Their Parent Companies
Brian L. Wilson • Thu, Nov 8, 2012 • 5 Comments

Æterna Zentaris Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Æterna Zentaris Inc. - Shareholder/Analyst Call
Thu, Apr 25
Æterna Zentaris Management Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 22
AEterna Zentaris' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 14, 2012

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto

PR Newswire (Wed, 7:30AM)
Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

PR Newswire (May 8, 2013)
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results

PR Newswire (May 7, 2013)
Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013

PR Newswire (Apr 23, 2013)
Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA

PR Newswire (Apr 17, 2013)
David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.

PR Newswire (Apr 15, 2013)
Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting

PR Newswire (Apr 10, 2013)
Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer

PR Newswire (Apr 10, 2013)
Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting

PR Newswire (Apr 3, 2013)
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial and Operating Results

PR Newswire (Mar 21, 2013)
Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference

PR Newswire (Mar 13, 2013)
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013

PR Newswire (Mar 12, 2013)
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation

PR Newswire (Mar 11, 2013)
Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer

PR Newswire (Feb 20, 2013)
Biotech's a Buy, but Hold Off on HMOs: Fund Manager

at CNBC.com (Jan 9, 2013)
Aeterna Zentaris Granted Special Protocol Assessment by the FDA for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108

PR Newswire (Dec 28, 2012)
Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients

PR Newswire (Dec 11, 2012)
Aeterna Zentaris to Present at Oppenheimer 23rd Annual Healthcare Conference in New York

PR Newswire (Dec 4, 2012)
Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

PR Newswire (Nov 26, 2012)
Aeterna Zentaris: Data Demonstrate that Perifosine Combined with Temsirolimus Was Well Tolerated in Phase 1 Trial in Malignant Glioma

PR Newswire (Nov 19, 2012)

AEZS vs. ETF Alternatives

Company Description

Currently, there's no company description for AEZS.

Sector: Healthcare

Industry: Biotechnology

Country: Canada

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 4:02 PM Aeterna Zentaris (AEZS +1.6%) moves up after posting a better than expected Q1. Zacks upgraded the shares to Outperform from Neutral on the back of the report with a price target of $2.10. Comment! [Healthcare, Earnings, On the Move]
Tuesday, May 7, 7:18 PM Aeterna Zentaris (AEZS): Q1 EPS of $0.07. Revenue of $16.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, April 17, 12:44 PM AEterna Zentaris (AEZS -2%) says it's agreed to transfer rights and grant a manufacturing license for Cetrotide to a subsidiary of Merck KGaA. It will receive a one-time payment of about $3.2M for the transaction, as well as certain other payments to execute a 36-month transitional services agreement to provide various transition services to assist Merck KGaA in assuming responsibility for manufacturing. Comment! [Healthcare, On the Move]
Monday, April 15, 11:30 AM AEterna Zentaris (AEZS -0.6%) appoints David A. Dodd as it's new president and CEO, succeeding Juergen Engel. Dodd was also appointed as a member of the company's board of directors. Comment! [Healthcare]
Thursday, April 11, 9:10 AM Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move]
Wednesday, April 10, 7:51 PM Aeterna Zentaris (AEZS) issues updated proof-of-concept results for its tumor treating Disorazol Z cytotoxic conjugates, such as AEZS-125 and AEZS-138. The company says results showed the compounds have high potential for the treatment of luteinizing hormone-releasing hormone receptor positive tumors, particularly in human ovarian and endometrial cancer xenograft models. Shares +19% AH. Comment! [Healthcare, On the Move]
Wednesday, April 10, 6:15 PM After-hours top gainers, as of 5:45 p.m.: AEZS +29%. ZUMZ +10%. PCYG +4%. BLK +4%. MDU +3%.
After-hours top losers: FTNT -15%. APOG -7%. EQIX -4%. FIRE -4%. YUM -3%. Comment! [On the Move]
Wednesday, April 10, 8:39 AM Aeterna Zentaris (AEZS) signs an agreement with Ergomed to carry out Phase III trials of Aeterna's AEZS-108 drug to treat endometrial cancer, the most common gynecologic malignancy. Ergomed will bear 30% of the costs, which are pegged at $30M, and conduct the study, as well as receive a share of any profits. (PR) Comment! [Healthcare]
Thursday, March 21, 5:24 PM More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well revenue. Total sales declined 24% Y/Y, mainly due to the recording of a $2.6M milestone payment from Yakult for the initiation of Phase 1 trials for perifosine in Japan during Q411. Operational expenses declined due to lower employee compensation and benefit costs and a reduced headcount at the drug developer. 2 Comments [Healthcare, Earnings]
Thursday, March 21, 4:24 PM Aeterna Zentaris (AEZS): Q4 EPS of -$0.29. Revenue of $9.5M . (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, March 11, 12:56 PM Midday top 10 gainers: CALI +52%. BOSC +45%. ESYS +30%. CBMX +25%. LAS +25%. PAMT +15%. FONR +15%. SCR +15%. SGOC +15%. RWC +14%.
Midday top 10 losers: AEZS -21%. NSU -11%. CSIQ -11%. SPEX -11%. FREE -10%. DKS -10%. CERE -10%. CNIT -9%. ONP -9%. RDCM -8%. Comment! [On the Move]
Monday, March 11, 12:13 PM Shares of Aetna Zentaris (AEZS) continue to plunge since their resumption of trading, now down 29% at $1.86 after an independent data safety monitoring board recommended discontinuing ongoing Phase 3 studies of perifosine. Comment! [Healthcare, On the Move]
Monday, March 11, 11:47 AM Aeterna Zentaris (AEZS) resumes trading -10%. Comment! [Healthcare, On the Move]
Monday, March 11, 11:33 AM Trading in Aeterna Zentaris (AEZS) will resume at 11:45 AM ET. Comment! [Healthcare]
Monday, March 11, 11:29 AM Shares of Aeterna Zentaris (AEZS -1.9%) remain halted after the company says an independent Data Safety Monitoring Board has recommended discontinuing ongoing Phase 3 studies comparing the efficacy and safety of perifosine in patients with relapsed or relapsed/refractory multiple myeloma. Based on its analysis, the DSMB reported that it was highly unlikely the study would achieve a significant difference in its primary endpoint. Comment! [Healthcare, On the Move]
Tuesday, January 29, 3:23 PM Shares of AEterna Zentaris (AEZS +18.5%) shares rocket higher in afternoon trading on the back of cancer drug peer Keryx Pharmaceuticals (KERX +40%) big gains. Volumes are extremely high in AEZS today, with over 4M shares changing hands, compared to the daily average of around 850K. 3 Comments [Healthcare, On the Move]

Ryan Mallory
Fuinhaz Setups for April 11 2013 | $AEZS $AMRS $ASML $CETV $GRPN $NFLX $VOD $ZNGA | http://bit.ly/YNtwJP
Apr 11, 9:07 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
$AEZS - Many gave Perifisone no chance after $KERX failure... Monday action likely the result of opportune shorts. http://bit.ly/cAHZ42
Mar 11, 1:37 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday ... $IMSC.PK, $AEZS, $KERX, $BBRY
Mar 6, 8:59 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

mr.lynch
articles from "experts" tends to shift biotech values by 10-15%, very strange but very profitable, made my $ back $300 @ time,hold $AEZS
Mar 2, 5:41 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: mr. lynch, glad you caught on. i noticed the trend months ago. it does however depend on which expert. bret jensen bump is the best.
Mar 4, 5:38 AM
• !Report Abuse
Add a reply...

140 characters

mr.lynch
I bought $AEZS @ $1.50 before reverse stock split, needless to say i lost $, but i learned how to make $ "day trading" volatile biotechs
Mar 2, 5:36 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

DJvatsu
Any suggestion on $AEZS for this week? It's suddenly dropping by almost 10%.
Jan 30, 1:45 PM
Reply (2)

• !Report Abuse
View all 2 replies
mr.lynch: year 2015 $AEZS may be trading @ $30, EASY, stock is volatile & risky but, pipeline is undeniable, HOLD HOLD HOLD/BUY
Mar 2, 5:44 PM
• !Report Abuse
mr.lynch: RESEARCH RESEARCH RESEARCH then put your profit into techs energy & real estate
Mar 2, 5:46 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$AEZS, buy @ $2.57 pre mkt.
Jan 3, 9:59 AM
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: Sell @ $2.70 (9:40), 5% gain. Sorry for posting delay.
Jan 3, 11:07 AM
• !Report Abuse
Add a reply...

140 characters

smokeyRose
Bought CLNE should have done that yesterday! sold a couple losers KERX & AEZS bunch of losers!!!! hope after pres speaks CLNE will JUMP!!
11/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

smokeyRose
AEZS KERX should I sell or hold??? thinking of Buying GUT or GABUX
11/14/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY
10/15/12
Reply (1)

• !Report Abuse
View all 1 replies
GVT: Any news on $IMSC ?
10/17/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

mr.lynch
articles from "experts" tends to shift biotech values by 10-15%, very strange but very profitable, made my $ back $300 @ time,hold $AEZS
Mar 2, 5:41 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: mr. lynch, glad you caught on. i noticed the trend months ago. it does however depend on which expert. bret jensen bump is the best.
Mar 4, 5:38 AM
• !Report Abuse
Add a reply...

140 characters

DJvatsu
Any suggestion on $AEZS for this week? It's suddenly dropping by almost 10%.
Jan 30, 1:45 PM
Reply (2)

• !Report Abuse
View all 2 replies
mr.lynch: year 2015 $AEZS may be trading @ $30, EASY, stock is volatile & risky but, pipeline is undeniable, HOLD HOLD HOLD/BUY
Mar 2, 5:44 PM
• !Report Abuse
mr.lynch: RESEARCH RESEARCH RESEARCH then put your profit into techs energy & real estate
Mar 2, 5:46 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$AEZS, buy @ $2.57 pre mkt.
Jan 3, 9:59 AM
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: Sell @ $2.70 (9:40), 5% gain. Sorry for posting delay.
Jan 3, 11:07 AM
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch ... $DNDN, $CPST, $ONCS.OB, $AEZS, $INO, $GE, $BAC ... more ... http://bit.ly/R6JcSY
10/15/12
Reply (1)

• !Report Abuse
View all 1 replies
GVT: Any news on $IMSC ?
10/17/12
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
$AMRN, $SSH, $NBS, $AEZS, $SIRI, $FCEL - Mid-Week Movers - http://bit.ly/QvWec9
10/4/12
Reply (1)

• !Report Abuse
View all 1 replies
wiesemc: Do you advise waiting until the AEZS split or purchase now?
10/4/12
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch - $BBRY, $CPST, $DNDN, $SGYP, $INO, $ONTY, $ONCS.OB, $AEZS, $FCEL - http://bit.ly/SX8eSw
9/30/12
Reply (1)

• !Report Abuse
View all 1 replies
NEInvPro: News today on SSH.
10/1/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ALIM, $ARNA, $AEZS, $ATRS, $PSDV mentioned in my new article due out pre market today.
6/27/12
Reply (10)

• !Report Abuse
View all 10 replies
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not?
6/27/12
• !Report Abuse
nkimidi: Hi Scott, what is a good price to buy ATRS?
6/27/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
KERX should not have given away perifosine rights to AEZS. Strongest data is for r/r MM. Study headed by Dr. Richardson at Dana-Farber
6/5/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Dr Richardson director of MM at Dana-F. He is not dumb enough to waste his time-effort if perifosine had NO possible chance of working
6/5/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
AEZS oversold? Thinking about a small position, thoughts?
4/10/12
Reply (1)

• !Report Abuse
View all 1 replies
xsilence: AEZS could rise a bit from here in anticipation of NDA filing later this year for AEZS-130.
4/12/12
• !Report Abuse
Add a reply...

140 characters

bernardo.zermeno
Now What?? AEZS and KERX down two days. Time to buy or just wait??
3/7/12
Reply (2)

• !Report Abuse
View all 2 replies
hotnutsjesus: lol, it went up because of the Jeremy Richards article and then the validity of the article/author was questioned. Looks kinda like a pump
3/7/12
• !Report Abuse
DAG1996: i was considering KERX until what happened over the past few days... now, i plan to wait at least a couple months to consider again
3/7/12
• !Report Abuse
Add a reply...

140 characters

MovingAvg
I wish the European crisis would end already! Messing up everything Long SSN AEZS COSWF.OB
3/6/12
Reply (3)

• !Report Abuse
View all 3 replies
sstonerm3: MovA, I added to my COSWF last October under $21. Getting close to time to get some more me thinks.
3/6/12
• !Report Abuse
MovingAvg: DaLatin ... Ugh
3/6/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
AEterna Zentaris' (AEZS) chart shows impressive support/resistance. Just from chart, one can guess stock will go up http://yhoo.it/yrhLvO
3/5/12
Reply (2)

• !Report Abuse
View all 2 replies
Funkengruven: It's been awhile... hopefully good things come to those that wait!
3/6/12
• !Report Abuse
mrmedusa: ahhh, for another THLD!
3/6/12
• !Report Abuse
Add a reply...

140 characters

A.G.C.M.
$AEZS / $KERX: perifosine 360th event has not occurred and DSMB has not told us event is "imminent." Still xpect top-line results in CTL-1
1/15/12
Reply (1)

• !Report Abuse
View all 1 replies
Andreas Braun: the more effective perifosine is the longer it takes to come to the 360th event
1/29/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
If AEZS's perifosine had absolutely no effect or was detrimental to colon CA patients, the DSMB would have stopped the trial in August.
12/9/11
Reply (1)

• !Report Abuse
View all 1 replies
Funkengruven: ;-) That's what I'm thinking!
12/9/11
• !Report Abuse
Add a reply...

140 characters

Derek Drayer
Any gossip on a AEZS buyout?
10/28/11
Reply (1)

• !Report Abuse
View all 1 replies
insidetrader2010: Thats all it is, is gossip.
11/30/11
• !Report Abuse
Add a reply...

140 characters

AEZS AEterna Zentaris, Inc.

AEZS

AEterna Zentaris, Inc.